THE RESTORATION OF HYPOTHALAMIC SIGNALING SYSTEMS AS ONE OF THE CAUSES TO IMPROVE THE METABOLIC PARAMETERS IN...

Area of Science:

• Endocrinology
• Metabolic Disorders
• Neuroscience

Background:

• Type 2 diabetes mellitus (T2DM) and its complications pose significant health challenges.
• Bromocryptine mesylate (BCM), a dopamine D2 receptor agonist, is explored for T2DM treatment.
• The precise mechanisms and efficacy of BCM in severe T2DM remain unclear.

Purpose of the Study:

• To investigate the effects of BCM on metabolic parameters in a rat model of neonatal T2DM.
• To examine the impact of BCM on the hypothalamic adenylyl cyclase signaling system (ACSS) in T2DM.

Main Methods:

• Male rats with a neonatal T2DM model were treated with BCM (300 mg/kg/day) for four weeks.
• Metabolic parameters including glucose tolerance, lipid profiles, and insulin utilization were assessed.
• Hypothalamic ACSS activity, gene expression (Mc4r), and receptor regulation (MC4R, DA2R, 5-HT1B) were analyzed.

Main Results:

• BCM treatment normalized glucose tolerance and improved exogenous insulin utilization.
• Lipid metabolism was normalized, with reduced triglycerides and atherogenic cholesterol.
• Hypothalamic regulation of ACSS by MC4R, DA2R, and 5-HT1B agonists was restored, alongside normalized Mc4r gene expression.
• BCM did not affect plasma insulin levels or pancreatic beta-cell function.

Conclusions:

• BCM demonstrates significant therapeutic potential for severe experimental T2DM.
• BCM's efficacy stems from restoring hypothalamic monoamine and melanocortin signaling pathways controlling energy metabolism and insulin sensitivity.